FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T

Journal of Neurochemistry

Volumn 106, Issue 1, 2008, Pages 121-133

  Gerard, Melanie ^a   Debyser, Zeger ^a   Desender, Linda ^a   Baert, Johan ^a   Brandt, Inger ^b   Baekelandt, Veerle ^a   Engelborghs, Yves ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Aggregation; Alpha synuclein; FK506 binding protein; Parkinson's disease; Peptidyl prolyl cis trans isomerase

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; MUTANT PROTEIN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; WILD TYPE;

ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; BRAIN; CATALYTIC DOMAIN; CELL LINE, TUMOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUTATION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLES; NEURONS; NONLINEAR DYNAMICS; PARKINSON DISEASE; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; TIME FACTORS;

EID: 45249118270     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05342.x     Document Type: Article

References (74)

1. Avramut M. Achim C. L. (2002) Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol. Behav. 77, 463 468.
2. Avramut M., Zeevi A. Achim C. L. (2001) The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. Brain Res. Dev. Brain Res. 132, 151 157.
3. Bertoncini C. W., Jung Y. S., Fernandez C. O., Hoyer W., Griesinger C., Jovin T. M. Zweckstetter M. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl Acad. Sci. USA 102, 1430 1435.
4. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G. Tabaton M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65 67.
5. Brecht S., Schwarze K., Waetzig V., Christner C., Heiland S., Fischer G., Sartor K. Herdegen T. (2003b) Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain. Neuroscience 120, 1037 1048.
6. Bultynck G., De Smet P., Rossi D., Callewaert G., Missiaen L., Sorrentino V., De Smedt H. Parys J. B. (2001a) Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor. Biochem. J. 354, 413 422.
7. Bultynck G., Rossi D., Callewaert G., Missiaen L., Sorrentino V., Parys J. B. De Smedt H. (2001b) The conserved sites for the FK506-binding proteins in ryanodine receptors and inositol 1,4,5-trisphosphate receptors are structurally and functionally different. J. Biol. Chem. 276, 47715 47724.
8. Bussell Jr R. Eliezer D. (2001) Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J. Biol. Chem. 276, 45996 46003.
9. Charters A. R., Kobayashi M. Butcher S. P. (1994a) Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. Biochem. Soc. Trans. 22, 411S.
10. Charters A. R., Kobayashi M. Butcher S. P. (1994b) The subcellular distribution of FK506 binding proteins in rat brain. Biochem. Soc. Trans. 22, 412S.
11. Chartier-Harlin M. C., Kachergus J., Roumier C. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167 1169.
12. Cherny D., Hoyer W., Subramaniam V. Jovin T. M. (2004) Double-stranded DNA stimulates the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an electron microscopy study. J. Mol. Biol. 344, 929 938.
13. Choi W., Zibaee S., Jakes R., Serpell L. C., Davletov B., Crowther R. A. Goedert M. (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576, 363 368.
14. Cohlberg J. A., Li J., Uversky V. N. Fink A. L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 41, 1502 1511.
15. Conway K. A., Harper J. D. Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318 1320.
16. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. Lansbury Jr P. T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571 576.
17. Coss M. C., Stephens R. M., Morrison D. K., Winterstein D., Smith L. M. Simek S. L. (1998) The immunophilin FKBP65 forms an association with the serine/threonine kinase c-Raf-1. Cell Growth Differ. 9, 41 48.
18. da Costa C. A., Ancolio K. Checler F. (2000) Wild-type but not Parkinson's disease-related ala-53 - > Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065 24069.
19. Feany M. B. Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394 398.
20. Fernandez C. O., Hoyer W., Zweckstetter M., Jares-Erijman E. A., Subramaniam V., Griesinger C. Jovin T. M. (2004) NMR of alpha-synuclein- polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J. 23, 2039 2046.
21. Fredenburg R. A., Rospigliosi C., Meray R. K., Kessler J. C., Lashuel H. A., Eliezer D. Lansbury Jr P. T. (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107 7118.
22. Fruman D. A., Burakoff S. J. Bierer B. E. (1994) Immunophilins in protein folding and immunosuppression. FASEB J. 8, 391 400.
23. Galat A. (2003) Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity - targets - functions. Curr. Top. Med. Chem. 3, 1315 1347.
24. Gerard M., Debyser Z., Desender L., Kahle P. J., Baert J., Baekelandt V. Engelborghs Y. (2006) The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J. 20, 524 526.
25. Gold B. G., Zeleny-Pooley M., Wang M. S., Chaturvedi P. Armistead D. M. (1997) A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp. Neurol. 147, 269 278.
26. Gold B. G., Densmore V., Shou W., Matzuk M. M. Gordon H. S. (1999) Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J. Pharmacol. Exp. Ther. 289, 1202 1210.
27. Gold B. G., Udina E., Bourdette D. Navarro X. (2004) Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurol. Res. 26, 371 380.
28. Gothel S. F. Marahiel M. A. (1999) Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol. Life Sci. 55, 423 436.
29. Guo X., Dawson V. L. Dawson T. M. (2001) Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur. J. Neurosci. 13, 1683 1693.
30. Han H., Weinreb P. H. Lansbury Jr P. T. (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 2, 163 169.
31. Harding M. W., Galat A., Uehling D. E. Schreiber S. L. (1989) A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341, 758 760.
32. Haynes C., Oldfield C. J., Ji F., Klitgord N., Cusick M. E., Radivojac P., Uversky V. N., Vidal M. Iakoucheva L. M. (2006) Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS Comput. Biol. 2, e100.
33. Heitman J., Movva N. R., Hiestand P. C. Hall M. N. (1991) FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 88, 1948 1952.
34. Hoyer W., Cherny D., Subramaniam V. Jovin T. M. (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43, 16233 16242.
35. Ibanez P., Bonnet A. M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A. Brice A. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169 1171.
36. Kahle P. J., Neumann M., Ozmen L. et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365 6373.
37. Kato H., Oikawa T., Otsuka K., Takahashi A. Itoyama Y. (2000) Postischemic changes in the immunophilin FKBP12 in the rat brain. Brain Res. Mol. Brain Res. 84, 58 66.
38. Kaylor J., Bodner N., Edridge S., Yamin G., Hong D. P. Fink A. L. (2005) Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J. Mol. Biol. 353, 357 372.
39. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780 2791.
40. Krebs M. R., Bromley E. H. Donald A. M. (2005) The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149, 30 37.
41. Krishnan S., Chi E. Y., Wood S. J. et al. (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42, 829 837.
42. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106 108.
43. Kullertz G., Luthe S. Fischer G. (1998) Semiautomated microtiter plate assay for monitoring peptidylprolyl cis/trans isomerase activity in normal and pathological human sera. Clin. Chem. 44, 502 508.
44. Labrande C., Velly L., Canolle B., Guillet B., Masmejean F., Nieoullon A. Pisano P. (2006) Neuroprotective effects of tacrolimus (FK506) in a model of ischemic cortical cell cultures: role of glutamate uptake and FK506 binding protein 12 kDa. Neuroscience 137, 231 239.
45. Lakso M., Vartiainen S., Moilanen A. M., Sirvio J., Thomas J. H., Nass R., Blakely R. D. Wong G. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165 172.
46. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B. Baekelandt V. (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13, 364 372.
47. Li J., Uversky V. N. Fink A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604 11613.
48. Li J., Uversky V. N. Fink A. L. (2002) Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23, 553 567.
49. Lin X. J., Zhang F., Xie Y. Y., Bao W. J., He J. H. Hu H. Y. (2006) Secondary structural formation of alpha-synuclein amyloids as revealed by g-factor of solid-state circular dichroism. Biopolymers ???, ??? ???.
50. Lo B. C., Ridet J. L., Schneider B. L., Deglon N. Aebischer P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813 10818.
51. Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843 9846.
52. Ohama E. Ikuta F. (1976) Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol. (Berl) 34, 311 319.
53. Park S. T., Aldape R. A., Futer O., DeCenzo M. T. Livingston D. J. (1992) PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. J. Biol. Chem. 267, 3316 3324.
54. Parsons W. H., Sigal N. H. Wyvratt M. J. (1993) FK-506: a novel immunosuppressant. Ann. N. Y. Acad. Sci. 685, 22 36.
55. Pirkl F. Buchner J. (2001) Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J. Mol. Biol. 308, 795 806.
56. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
57. Receveur-Brechot V., Bourhis J. M., Uversky V. N., Canard B. Longhi S. (2006) Assessing protein disorder and induced folding. Proteins 62, 24 45.
58. Rosen M. K., Standaert R. F., Galat A., Nakatsuka M. Schreiber S. L. (1990) Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. Science 248, 863 866.
59. Scholz C., Rahfeld J., Fischer G. Schmid F. X. (1997) Catalysis of protein folding by parvulin. J. Mol. Biol. 273, 752 762.
60. Serpell L. C., Berriman J., Jakes R., Goedert M. Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 4897 4902.
61. Singleton A. B., Farrer M., Johnson J. et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
62. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. Goedert M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469 6473.
63. Steiner J. P., Dawson T. M., Fotuhi M., Glatt C. E., Snowman A. M., Cohen N. Snyder S. H. (1992) High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 358, 584 587.
64. Timerman A. P., Wiederrecht G., Marcy A. Fleischer S. (1995) Characterization of an exchange reaction between soluble FKBP-12 and the FKBP ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. J. Biol. Chem. 270, 2451 2459.
65. Tradler T., Stoller G., Rucknagel K. P., Schierhorn A., Rahfeld J. U. Fischer G. (1997) Comparative mutational analysis of peptidyl prolyl cis/trans isomerases: active sites of Escherichia coli trigger factor and human FKBP12. FEBS Lett. 407, 184 190.
66. Uversky V. N. Fink A. L. (2002) Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522, 9 13.
67. Uversky V. N., Li J. Fink A. L. (2001a) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737 10744.
68. Uversky V. N., Li J. Fink A. L. (2001b) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284 44296.
69. Van Duyne G. D., Standaert R. F., Karplus P. A., Schreiber S. L. Clardy J. (1991) Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 252, 839 842.
70. Van Duyne G. D., Standaert R. F., Karplus P. A., Schreiber S. L. Clardy J. (1993) Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J. Mol. Biol. 229, 105 124.
71. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M. Biere A. L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509 19512.
72. Xin H. B., Timerman A. P., Onoue H., Wiederrecht G. J. Fleischer S. (1995) Affinity purification of the ryanodine receptor/calcium release channel from fast twitch skeletal muscle based on its tight association with FKBP12. Biochem. Biophys. Res. Commun. 214, 263 270.
73. Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164 173.
74. Zeng B., MacDonald J. R., Bann J. G., Beck K., Gambee J. E., Boswell B. A. Bachinger H. P. (1998) Chicken FK506-binding protein, FKBP65, a member of the FKBP family of peptidylprolyl cis-trans isomerases is only partially inhibited by FK506. Biochem. J. 330, 109 114.